(median, MiVI 39.0 vs MaVI 21.0 months, HR 0.7; 95%CI, 0.5-0.8; P = 0.002). Whereas nodal metastasis, R1 margin, and postoperative morbidity were associated with early death (≤18 months) among patients with MiVI, only nodal metastasis was associated with late (>18 months) prognosis. resection is currently the only potentially curative treatment option for patients with ICC. 3 However, long-term survival after curative resection among patients with ICC is disappointing.
Conclusions
Specifically, 5-year survival after resection has been reported to be only 20%-35% with over two-thirds of patients experiencing recurrence. [4] [5] [6] The vascular invasion has been identified as one of the strongest risk factors contributing to recurrence and death of patients with ICC after surgery. 7, 8 The 7th and 8th editions of the American Joint Committee on Cancer (AJCC) staging manual incorporate vascular invasion within the T category designation. 9 Macrovascular invasion (MaVI) is defined as tumor invasion into a major vessel that can be identified by radiological imaging or macroscopic examination. In contrast, the diagnosis of microvascular invasion (MiVI) is largely dependent on histological examination. 10 Generally, MiVi has been defined as the presence of tumor emboli in a portal radical vein, large capsule vessel, or in a vascular space lined by endothelial cells. 10 MiVI has been extensively studied and reported to be a strong indicator of worse outcomes among patients with hepatocellular carcinoma (HCC) after resection or liver transplantation. [10] [11] [12] [13] [14] [15] [16] [17] In fact, MiVI is now recognized as the main cause of MaVI and intrahepatic metastasis among patients with HCC. 18 In turn, HCC with histologically confirmed
MiVI have a high risk of recurrence after resection and several studies have suggested that adjuvant therapies, such as transarterial chemotherapy and embolization 19, 20 and sorafenib, 21 may improve the outcome of these patients. In contrast, the potential impact of MiVI on the long-term outcome of patients with ICC has not been well investigated. As such, the objective of the present study was to define the clinical impact of MiVI on the prognosis of patients after curative-intent resection of ICC using a large, multiinstitutional, international database. 
| PATIENTS AND METHODS

| Study cohort
| Data collection and follow-up
Preoperative variables, including standard demographic, clinicopathological, and tumor-related characteristics, were collected using a standardized data sheet. All resected specimens were subjected to histological analysis and were evaluated for tumor size, number, morphology, differentiation, margin, vascular, biliary and perineural invasion, lymph node status, as well as adjacent organ invasion. MaVI was defined as invasion of the tumor into a major vessel that was identified during the macroscopic examination or radiographic imaging; MiVI was defined as tumor invasion of hepatic veins, portal system, and lymphatic ducts that were visible only on microscopy. 10, 15 An R0 resection was defined as a minimum margin length of >1 mm; the microscopic presence of tumor at the margin or a minimum margin length of ≤1 mm was designated as an R1 resection. Pathologic staging was assigned according to the 8th edition American Joint Committee on Cancer (AJCC) staging guidelines. 9 Details of the operation were documented and collected, including resection mode, lymphadenectomy, operation time, and intraoperative blood loss.
After discharge, all patients were regularly followed with serum carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and imaging studies, including abdominal ultrasonography, computed tomography and/or magnetic resonance imaging (MRI) until the death of the patient or the end of the study. In the present study, the primary endpoints were overall survival (OS) and disease-free survival (DFS). OS was defined as the time duration from the date of initial resection to patient death or the end of the study. DFS was defined as the time duration from the date of initial surgery to tumor recurrence.
Recurrence was defined as suspicious imaging findings or biopsyproven tumor. The site of recurrence was categorized as intrahepatic and/or extrahepatic. Treatments of recurrence were tailored according to the tumor burden and general condition of the patient. Curativeintent therapies for recurrence included surgical re-resection, ablation, or combined resection plus ablation. 3 | RESULTS (Table 1) . Although tumor size and number, as well as serum markers (ie Ca19-9 and CEA) were not different among the three groups, tumors with either macro-or MiVI had a higher incidence of perineural, biliary and adjacent organ invasion, as well as the presence of satellite lesions (all P < 0.01). In addition, patients with vascular invasion were more likely to have advanced AJCC T disease, lymph node metastasis, and poor tumor differentiation vs patients with NoVI (all P < 0.05). Although patients with macro-or MiVI were more likely to undergo a major hepatectomy and concomitant lymphadenectomy (both P < 0.01), the incidence of an R0 resection was lower among patients with vs without vascular invasion (MaVI 79.2%, MiVI 80.3% vs NoVI 92.0%; P < 0.001).
| Statistical analysis
| Baseline characteristics
Among patients who had the vascular invasion, patients with MaVI had a higher incidence of adjacent organ invasion (13.4% vs 5.6%), nodal metastasis (37.7% vs 22.9%) compared with patients who had MiVI (all P < 0.05). In contrast, tumor size, number, as well as the incidence of the perineural and biliary invasion were equivalent among patients with
MaVI vs MiVI. The frequency of adjuvant chemo-and radiotherapy was comparable among patients with MiVI and MaVI; of note, the use of chemotherapy among these patients was higher than patients without vascular invasion (MiVI 38.3%, MaVI 39.8% vs NoVI 24.7%; P < 0.001).
| Survival of patients stratified by vascular invasion
After a median follow-up of 35 (range 3-211) months, a total of 553 (50.8%) patients had died. In examining the entire cohort, 1-, 3-and On multivariable analysis, after taking into account competing risk factors, MaVI (HR 1.5; 95%CI, 1.1-1.9; P = 0.005), rather than MiVI (HR 1.1; 95%CI, 0.9-1.3; P = 0.379), was associated with worse long-term survival (Table 2 ). In contrast, both MaVI (HR 1.4; 95%CI, 1.0-1.8; P = 0.022) and MiVI (HR 1.6; 95%CI, 1.3-2.0; P < 0.001), tumor size, number, and differentiation, as well as lymph node status were correlated with risk of tumor recurrence (Table 3 ). 
| Recurrence and treatments
| Survival of patients with MiVI: Early death versus long-term survival
In examining OS of patients with MiVI vs MaVI, long-term survival was initially generally similar, yet became divergent beginning roughly around 18 months after surgery (cumulative survival rate at 18 months, MiVI 63.9% vs MaVI 55.5%; P = 0.01) ( Figure 1A) .
Overall, 79 patients with MiVI died within 18 months after initial surgery (early death), whereas 118 patients survived longer than 18 months (long-term survival). Patients who died within 18 months after initial surgery were more likely to have multiple tumors (26.6% vs 13.6%; P = 0.054), lymph node metastasis (32.9% vs 16.0%; P = 0.024), and an R1 resection (31.6% vs 13.6%; P = 0.003) ( Table 4) (Table 5 ). In contrast, among the 118 patients who survived longer than 18 months after initial surgery, only lymph node metastasis was correlated with late death (after 18 months) (HR 3.3; 95%CI, 1.5-7.0; P = 0.002) ( Table 6 ).
T intrahepatic recurrence or systematic metastasis. 10 MiVI has been reported to be an independent predictor of tumor recurrence and mortality after resection or transplantation of HCC. [10] [11] [12] [13] [14] [15] [16] [17] In turn,
MiVI is commonly utilized in the pathological assessment and prognostic stratification of patients with HCC. [10] [11] [12] [13] [14] [15] [16] [17] Data in the present study demonstrated that MiVI was an independent risk factor for tumor recurrence, but not long-term survival among patients with ICC. Specifically, patients with only MiVI had the same DFS compared with patients who had MaVI, as well as a comparable recurrence pattern (intrahepatic recurrence: 58.2% vs 57.8%).
Interestingly, previous data had suggested that AJCC stage II HCC patients with MiVI had similar outcomes as patients with multiple tumors, implying that MiVI was a strong risk factor for intrahepatic recurrence. 13 In the present study, patients with ICC and histologically confirmed MiVI or MaVI had a higher incidence of perineural and biliary invasion, satellite lesions, advanced AJCC T stages, nodal metastasis, and poor differentiation. In examining survival, patients with MiVI had a comparable prognosis as patients with MaVI within the first 1 to 2 years after surgery yet diverged at 18 to 24 months. Previous work from our group had suggested that the timing of early vs late recurrence among patients with ICC could be defined empirically using a cutoff of about 2 years. 6 In addition, among patients who did recur, the overwhelming majority recurred early. Similarly, in the present study, we were able to identify two prognostic cohorts among patients who had MiVI. In particular, there was a subset of patients who experienced early recurrence and death within the first 18 to 24 months after surgery. Interestingly, on multivariable analysis, factors associated with early mortality included multiple tumors (26.6% vs 13.6%; P = 0.054), lymph node metastasis (32.9% vs 16.0%; P = 0.024), and an R1 resection (31.6% vs 13.6%; P = 0.003). 5, [27] [28] [29] [30] [31] In contrast, among patients who were late survivors, the only factor associated with prognosis was lymph node metastasis, as patients with the nodal disease had a threefold increased risk of late death (HR 3.3; 95% CI 1.5-7.0; P = 0.002). Lymph node status has previously been documented as one of the strongest prognostic factors associated with outcomes among patients with ICC. [32] [33] [34] [35] [36] [37] [38] The present study highlights how lymph node status remained a strong indicator of prognosis even among patients with other risk factors such as Abbreviations: CI, confidence intervals; OR, odds ratio.
